Assistant Professor, Obstetrics and Gynecology, Perelman School of Medicine

Obstetrics & Gynecology

Dr. Janos L. Tanyi, MD

Janos Tanyi is an expert in the field of Obstetrics & Gynecology. He studied medicine at Baylor College of Medicine. He received 2 awards: "CMS Meaningful Use Stage 1 Certification" and "Fellow (FACOG)". Janos L. Tanyi, MD is also a published MD. He has 36 paper published. The most recent paper is: [Postpartum hysterectomy]. Janos Tanyi accepts Medicare.

Publications

A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer.
Immunotherapy for ovarian Cancer: recent advances and perspectives.
Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian Cancer.
A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside.
Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients.
mir-30d Regulates multiple genes in the autophagy pathway and impairs autophagy process in human Cancer cells.
Evaluation of Pegylated Liposomal Doxorubicin Dose on the Adverse Drug Event Profile and Outcomes in Treatment of Recurrent Endometrial Cancer.
The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast Cancer.
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian Cancer.
Dendritic cell-based tumor vaccinations in epithelial ovarian Cancer: a systematic review.
Reversible paraneoplastic encephalitis in three patients with Ovarian neoplasms.
lin-28 homologue A (LIN28A) promotes cell cycle progression via the regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homol...
Oncology biomarkers for gynecologic malignancies.
Clinical predictors of bevacizumab-associated gastrointestinal perforation.
Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: a clinically recalcitrant entity.
Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian Cancer.
Balloon tamponade of hemorrhage after Uterine curettage for gestational trophoblastic disease.
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian Cancer.
The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian Cancer cells: validation of the lysophosphatidic acid signaling ca...
Identification of tissue- and Cancer-selective promoters for the introduction of genes into human ovarian Cancer cells.
Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a pro...
Specific keynote: molecular therapeutics in ovarian Cancer.
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian Cancer.
Lysophosphatidic acid production and action: validated targets in Cancer?
Primary neuroendocrine Carcinoma of the vagina with Merkel cell Carcinoma phenotype.
Papillary thyroid Cancer arising in struma ovarii.
Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian Carcinomas*.
Trisomy 12 in juvenile granulosa cell tumor of the ovary during pregnancy. A report of two cases.
[Mutation analysis of the beta-catenin gene in epithelial Carcinomas of the ovaries].
[Atypical process of acute disturbance of liver function with severe thrombocytopenia in the third trimester].
Analysis of p53 mutation and cyclin D1 expression in breast tumors.
[Postpartum hysterectomy].
Identification of multiple novel protein biomarkers shed by human serous Ovarian tumors into the blood of immunocompromised mice and verified in patient sera.
Placenta percreta at 7th week of pregnancy in a woman with previous caesarean section.
Lysophosphatidic acid is a bioactive mediator in ovarian Cancer.

Procedures Preformed

Colpopexy
Colporrhaphy
Colposcopy
Destruction or Excision of Lesion of Cervix (incl. LEEP)
View All

Conditions Treated

Carcinoma in Situ
Cervical Cancer
Cervical Polyps
Endometriosis
View All

Doctors Specialties

Gynecologic Oncology
Obstetrics
Gynecology

Accepted Insurances

Awards

CMS Meaningful Use Stage 1 Certification
Fellow (FACOG)

Education

Baylor College of Medicine
University of Debrecen Medical and Health Science Center

Hospital

Hospital of the University of Pennsylvania
Pennsylvania Hospital

Drug Facts

NPI NUMBER		1649433319
NPPES Provider LastName		TANYI
NPPES Provider FirstName		JANOS
NPPES Provider ZIPCode		191044206
NPPES Provider State		PA
Specialty Description		Gynecological/Oncology
Total Claim Count		114.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1649433319
Last Name Of The Provider	TANYI
First Name Of The Provider	JANOS
View All

Similar Doctors

	Dr. Cathy K. Dratman, MD This Doctor is OpenDoctor Recommended.
	Dr. Alexis C. Gimovsky, MD This Doctor is OpenDoctor Recommended.
	Dr. Jamie A. Bastek, MD This Doctor is OpenDoctor Recommended.
	Dr. Michail Spiliopoulos, MD This Doctor is OpenDoctor Recommended.
	Dr. James S. Ferriss, MD This Doctor is OpenDoctor Recommended.
	Dr. Corina D. Tennant, MD This Doctor is OpenDoctor Recommended.
	Dr. Peter G. O'Hare III, MD This Doctor is OpenDoctor Recommended.
	Dr. Holly W. Cummings, MD This Doctor is OpenDoctor Recommended.
	Dr. Frances R. Batzer, MD This Doctor is OpenDoctor Recommended.
	Dr. Karen M. Berkowitz, MD This Doctor is OpenDoctor Recommended.